The FDA Allows Approved Nicotine Pouches to Advertise
The FDA allows approved nicotine pouches to advertise that they’re less harmful than cigarettes.
US FDA News Release, ‘FDA grants first-ever modified risk orders to eight smokeless tobacco products FDA concludes completely switching from cigarettes to these authorized products lowers certain health risks,’ October 2019.
- In 2019 the US Food & Drug Administration (FDA) granted risk modified orders to eight Swedish-style nicotine products.
- The products were given the right to advertise with the claim: “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
- The FDA came to this conclusion following an exhaustive scientific review, including long-term epidemiological studies.
- The FDA stated that the “available evidence does not demonstrate significant youth initiation of these products.”
- According to the FDA’s statement, these pouches “will significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole.”
Nicotine Pouch Related Research
- Nicotine pouches have decreased smoking rates to 7% in Sweden
- Swedish men have a lower tobacco-related mortality rate
- The FDA allows approved nicotine pouches to advertise
- Sweden’s tobacco consumption patterns could save 355,000 lives
- Nicotine pouches have similar risks as NRTs
- Nicotine pouches are not a gateway to smoking
- Swedish-style nicotine pouches do not increase cancer risk
- Nicotine pouches have similar toxicant levels to NRTs